histamine dihydrochloride + aldesleukin + azacitidine

This is a combination therapy consisting of three agents: histamine dihydrochloride, aldesleukin, and azacitidine. Histamine dihydrochloride is a synthetic derivative of the biogenic amine histamine that inhibits the formation of immunosuppressive oxygen radicals in myeloid cells by targeting NADPH oxidase 2 via H2-type histamine receptors. This action protects T-cells and natural killer (NK) cells from oxidative inhibition and apoptosis[4][6]. Aldesleukin is a recombinant form of interleukin 2 (IL‑2), a cytokine that stimulates proliferation and activation of T-cells and NK cells[4][5]. When used together, these two agents enhance immune-mediated destruction of leukemic cells. Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity; it incorporates into RNA and DNA to disrupt their metabolism, inhibits protein synthesis, induces cytotoxicity in abnormal hematopoietic cells, and acts as a hypomethylating agent by inhibiting DNA methyltransferase[1][8]. This combination may be explored for maintenance therapy or relapse prevention in acute myeloid leukemia (AML), leveraging both immunomodulatory effects (histamine dihydrochloride + aldesleukin) and direct anti-leukemic activity/hypomethylation from azacitidine.

Other names

HDC (for histamine dihydrochloride)IL-2 (for aldesleukin)5-Azacytidine (for azacitidine)